GV, the venture capital arm of Google parent company Alphabet, is among the investors pouring $72.5 million into a company using mitochondrial biology to treat disease.
The Sept. 12 series A funding round helped launch Pretzel Therapeutics, which aims to develop novel therapies for conditions affected by dysfunctional mitochondria, including Alzheimer's and Parkinson's diseases.
"The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as well as common diseases of aging," said Jay Parrish, PhD, board chair and CEO of Pretzel, in a Sept. 12 company news release.
Pretzel's scientific advisory board consists of two Nobel laureates. Arch Venture Partners and Mubadala Capital led the investment round.